Raygent Biopharmaceutical Stock Portfolio beats the market for 2008

buy modafinil israel My biotech picks were published in Genetic Engineering News (GEN) in February 2008. My strategy was to allocate 25% in one ETF (XBI), 50% in large caps and 25% in smaller cap biotechs. My proprietary system is based on technicals, core technology and company financials. Despite all the volatility in 2008 with declines of 34-40% for the major indices my bioportfolio had a gain of about 9% due to a 75% weighting of large and mid cap biopharmaceuticals. A huge gain of 30% as of August 15, 2008 was pared during the 4th Quarter meltdown. Microcap stocks with the exception of MITI (MicroMet) suffered large losses and 2009 should be a difficult year for companies with weak balance sheets. My 2009 forecast will be published in the February GEN.

http://thebaglab.com/shop/?swoof=1 Among the big winners in the portfolio were:

  • AMGN Amgen up 23%
  • DNA Genentech up 18%
  • CEPH Cephalon up 18%
  • GILD Gilead up 14%
  • CBST Cubist up 34%
  • MATK Martech up 8%
  • MYGN Myriad Genetics up 65%
  • VPHM Viropharma up 45%
  • XBI ETF was down 2.5%

buy Maxalt rizatriptan Some of my long term holds BDX BIIB ELN and GENZ were down significantly. The iShares Biotech ETF symbol IBB was down about 10% for 2008 much better than the NASDAQ composite down 40% YTD. Read the complete story, here.

The main drivers of this market as reviewed in the article were M&A, product announcements, revenue and value.

Here are some of the picks:

Stock Company Weighting 2/1/08 8/15/08 YTD return % 12/31/08 YTD return %
XBI ETF S&P Bio 25% 55 69 25.5 53.6 -2.5%
Large Caps Buys 50% 9%
AMGN Amgen 47 65 38.45 57.75 23%
CELG Celgene 59 75.9 28.6 55.3 -6.3%
CEPH Cephalon 65 77 77 18.5%
DNA Genentech 70 98.25 40.35 82.9 18.4%
PFE Pfizer 22 20 -9.3 17.7 -19.5%
Mid/SmallCap buys 25% 3%
ALNY Alnylam 30 34.75 15.8 24.7 -17.5%
CBST Cubist 18 23.55 30.8 24.2 34.2%
CRA Celera 15 14.5 -3.33 11 -26%
ELN Elan 26 10 -61 6 -77%
EPIX Epix 3 1.92 -36 1 -66%
ISIS Isis 15 19.1 27.2 14.2 -5.5%
MATK Martech Biosciences 28 37.7 34.7 30.3 8.25%
MYGN Myriad Genetics 40 65.5 63.75 66.2 66%
SGEN Seattle Genetics 9 12.15 34.9 8.95 -1%
VPHM ViroPharma 9 13.9 54.5 13 45%
Return YTD +30% 5-9%
No comments yet.

Leave a Reply